Introduction:
In late 2019, a novel corona virus, severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2), was identified in the human body and led to a pandemic [1]. Understanding the spectrum of this disease, it’s prevention and optimal clinical management is the current focus of physicians and researchers around the globe. Many drugs have been and are being investigated for their role in the management of COVID-19 infection. Remdesevir has shown potential in decreasing hospital stay among COVID-19 infected patients [2]. Dexamethasone has shown a mortality benefit in severe COVID-19 [3]. However, the current management of SARS-CoV-2 pneumonia and ARDS focuses mainly on providing supportive measures [4].
The clinical course in COVID-19 varies from asymptomatic disease to fulminant ARDS [5]. There is anecdotal evidence about persisting dyspnea following treatment of COVID-19. Post-COVID pulmonary fibrosis is hypothesized to be one of the etiologies behind this phenomenon [6].Also, post- treatment; an asymptomatic patient may develop a subclinical infectious process. This subclinical infection may lead to a second phase of desaturation. There are currently no guidelines on the treatment of this second phase of desaturation. We present a case monitored the response of steroids in our patient who had desaturation secondary to an ongoing residual subclinical inflammation after he was treated for COVID-19 pneumonia. Our patient had an excellent response to steroids; hence we postulate that steroids can be a potential treatment for such patients.